The trade group representing Australia’s biotech industry has moved to clear up confusion over the proposed Australian Innovation and Manufacturing’ (AIM) Incentive.
AusBiotech and others have called for the introduction of this incentive in order to make sure Australian research and development-based intellectual property (IP) is developed and supported within Australia, delivering value to the country and its biotech industry as it reaches commercialization.
The group has now responded to criticism of AIM by accusing critics of not reading the proposal correctly.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze